Table 1 Baseline characteristics of participants to the Montrachet study (n = 1153), according to their inclusion in the present study
Baseline characteristics | Included | Not included n = 343 | P |
|---|---|---|---|
n = 810 | |||
Age, years | 82.11 ± 3.67 | 82.59 ± 3.89 | 0.046 |
Sex | |||
 Male | 292 (36.05) | 138 (40.23) | 0.179 |
Smoking status, yes, n = 1132 | 282 (35.43) | 108 (32.14) | 0.288 |
Alcohol consumption, yes, n = 1017 | 46 (6.30) | 18 (6.27) | 0.986 |
Body mass index | 379 (46.79) | 175 (51.02) | 0.189 |
Diabetic retinopathy, n = 1016 | 7 (0.86) | 2 (0.58) | 1.00 |
Age-related macular degeneration (AMD) stage, n = 1068 |  |  | 0.350 |
 No AMD | 412 (54.71) | 175 (55.56) |  |
 Early AMD 1 | 235 (31.21) | 102 (32.38) |  |
 Early AMD 2 | 78 (10.36) | 22 (6.98) |  |
 Early AMD 3 | 15 (1.99) | 7 (2.22) |  |
 Late AMD | 13 (1.73) | 9 (2.86) |  |
Intraocular pressure, mmHg | 15.49 ± 3.32 | 15.44 ± 3.64 | 0.844 |
Cup/Disc ratio n = 1111 | 0.36 ± 0.22 | 0.38 ± 0.21 | 0.179 |
Axial length, mm, n = 955 | 23.44 ± 1.30 | 23.46 ± 1.39 | 0.845 |
Antihypertensive treatment, n = 1017 | 442 (60.55) | 173 (60.28) | 0.937 |
Lipid lowering drug use, n = 1017 | 311 (42.60) | 113 (39.37) | 0.347 |
Plasma total cholesterol, mmol/l, n = 1139 | 5.80 ± 0.96 | 5.78 ± 0.92 | 0.649 |
 Low density lipoprotein, mmol/l | 3.61 ± 0.96 | 3.59 ± 0.81 | 0.759 |
  High density lipoprotein, mmol/l | 1.67 ± 0.40 | 1.65 ± 0.41 | 0.354 |
 Triglycerides, mmol/l | 1.17 ± 0.50 | 1.20 ± 0.55 | 0.384 |